JP2016185981A5 - - Google Patents

Download PDF

Info

Publication number
JP2016185981A5
JP2016185981A5 JP2016137228A JP2016137228A JP2016185981A5 JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5 JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5
Authority
JP
Japan
Prior art keywords
seq
chain
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016137228A
Other languages
English (en)
Japanese (ja)
Other versions
JP6162864B2 (ja
JP2016185981A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016185981A publication Critical patent/JP2016185981A/ja
Publication of JP2016185981A5 publication Critical patent/JP2016185981A5/ja
Application granted granted Critical
Publication of JP6162864B2 publication Critical patent/JP6162864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016137228A 2006-08-14 2016-07-12 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 Active JP6162864B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006221230 2006-08-14
JP2006221230 2006-08-14
JP2007019108 2007-01-30
JP2007019108 2007-01-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014175480A Division JP5972325B2 (ja) 2006-08-14 2014-08-29 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Publications (3)

Publication Number Publication Date
JP2016185981A JP2016185981A (ja) 2016-10-27
JP2016185981A5 true JP2016185981A5 (enExample) 2017-04-13
JP6162864B2 JP6162864B2 (ja) 2017-07-12

Family

ID=39082111

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008529863A Active JP5317697B2 (ja) 2006-08-14 2007-08-14 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2013043041A Active JP5651726B2 (ja) 2006-08-14 2013-03-05 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2014175480A Active JP5972325B2 (ja) 2006-08-14 2014-08-29 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2016137228A Active JP6162864B2 (ja) 2006-08-14 2016-07-12 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2008529863A Active JP5317697B2 (ja) 2006-08-14 2007-08-14 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2013043041A Active JP5651726B2 (ja) 2006-08-14 2013-03-05 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2014175480A Active JP5972325B2 (ja) 2006-08-14 2014-08-29 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Country Status (7)

Country Link
US (2) US20100092457A1 (enExample)
EP (3) EP2548576B1 (enExample)
JP (4) JP5317697B2 (enExample)
AU (1) AU2007285217B2 (enExample)
BR (1) BRPI0713086A2 (enExample)
CA (1) CA2658050A1 (enExample)
WO (1) WO2008020586A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414105T1 (de) * 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
US20080206229A1 (en) * 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
WO2005100560A1 (ja) * 2004-04-09 2005-10-27 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
EP1870458B1 (en) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
AU2006256030B2 (en) * 2005-06-10 2012-06-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CN101237890A (zh) * 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
CL2007002057A1 (es) * 2006-07-13 2008-01-11 Chugai Pharmaceutical Co Ltd Diacuerpo anti-antigeno leucocitario humano (hla), usos del diacuerpo para preparar un medicamento util como inductor de muerte celular, supresor del crecimeinto celular o como agente antitumoral.
CA2658050A1 (en) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-desmoglein 3 antibodies
US8470323B2 (en) * 2007-01-09 2013-06-25 The Trustees Of The University Of Pennsylvania Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
EP2623592B1 (en) 2010-09-28 2019-05-15 NB Health Laboratory Co. Ltd. Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
EP2908133B1 (en) * 2012-10-09 2018-07-04 Konica Minolta, Inc. Method for detecting squamous cell carcinoma
WO2014100220A2 (en) * 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
WO2017147247A1 (en) * 2016-02-23 2017-08-31 Pires Eusebio S Anti-sas1b antibodies and methods of use
EP3568158A4 (en) 2017-01-11 2020-11-18 The Board of Trustees of the Leland Stanford Junior University R-SPONDIN SUBSTITUTION MOLECULES (RSPO)
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
US12103972B2 (en) 2018-04-06 2024-10-01 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
EP3820499A4 (en) 2018-07-09 2022-07-13 Surrozen Operating, Inc. TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES
US20240075161A1 (en) * 2019-10-28 2024-03-07 Augusta University Research Institute, Inc. Engineered exosomes to detect and deplete pro-tumorigenic macrophages
CA3198268A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
CN113476601B (zh) * 2021-08-24 2022-05-20 知佰幸细胞库(浙江)有限公司 干细胞细胞因子联合海藻多糖制备的药物或化妆品
WO2023114847A2 (en) * 2021-12-14 2023-06-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU3657899A (en) * 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999057149A2 (en) 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
WO2003020769A1 (en) 2001-09-04 2003-03-13 Keio University Pemphigus monoclonal antibody
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20060057559A1 (en) * 2004-06-23 2006-03-16 Rigel Pharmaceuticals, Inc. High-throughput cell migration screening assay
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
CA2658050A1 (en) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-desmoglein 3 antibodies

Similar Documents

Publication Publication Date Title
JP2020501532A5 (enExample)
JP2017176174A5 (enExample)
JP2017114866A5 (enExample)
JP2020022464A5 (enExample)
JP2018504907A5 (enExample)
JP2016196468A5 (enExample)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MX392340B (es) Anticuerpo anti cd73 humana.
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2013539454A5 (enExample)
JP2013539361A5 (enExample)
JP2012116856A5 (enExample)
JP2012126742A5 (enExample)
JP2014012688A5 (enExample)
JP2016538830A5 (enExample)
JP2020500538A5 (enExample)
JP2012143232A5 (enExample)
JP2013538057A5 (enExample)
JP2011526480A5 (enExample)
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
JP2017528117A5 (enExample)
JP2017508475A5 (enExample)
JP2011155981A5 (enExample)
JP2016116527A5 (enExample)
NZ630847A (en) Anti-sema4d antibodies and epitopes